Exchange: NASDAQ·Updated 07:30 PM EDT

VERA News

News
all
press releases
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.
Zacks
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.
Zacks
More News
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.
Stocktwits
VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4
Vera Therapeutics stated that Trutakna's commercial launch generated more than 350 patient start forms in the first 10 weeks.
Stocktwits
Futures Drop As Yields, Oil Prices Keep Rising
Futures Drop As Yields, Oil Prices Keep Rising Futures are lower - but well off session lows thanks to some well-time oil sell orders just before US traders walked in to work - as bond yields continue to make new highs, with both Nasdaq and Russell lagging the S&P which feels like...
Zero Hedge
VERA’s TRUTAKNA Stuns in Two-Year Data and Full-Approval Jackpot Is Now in Sight
Vera Therapeutics (NASDAQ:VERA) has delivered the kind of clinical readout that can fundamentally change the investment narrative around a commercial-stage biotech: its TRUTAKNA (atacicept-vymj) program has produced two-year data showing stabilization of kidney function and a dramatic reduction in kidney disease progression in patients with IgA nephropathy (IgAN).
24-7 Market News
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics
Vera Therapeutics' Trutakna received an early, fast-tracked approval from the FDA to reduce proteinuria in adults with primary IgA Nephropathy whose health is at risk of deterioration.
Stocktwits
Why Is Vera Therapeutics Stock Gaining Tuesday?
Vera Therapeutics (VERA) stock jumps 9% following FDA accelerated approval for its kidney disease drug Trutakna. Full analysis here.read more...
Benzinga
VERA Stock Rallies Ahead Of High-Stakes FDA Decision On Lead Kidney Disease Drug – Retail Sees 35% Potential Upside
The U.S. Food and Drug Administration is set to announce its decision on Atacicept later on Monday, paving the way for the potential commercialization of the drug in the U.S.
Stocktwits
Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment
The biotech moves a step closer to full approval in IgAN as regulators agree to an accelerated timeline for key kidney function data review.
Stocktwits
Pictet Asset Management Holding SA Cuts Stake in Vera Therapeutics, Inc. $VERA
Pictet Asset Management Holding SA cut its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 3.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,392,421 shares of the company's stock after sellin...
MarketBeat

Advertisement|Remove ads.